Posted by Michael Wonder on 29 Sep 2021
Selux Diagnostics earns FDA breakthrough device designation for next generation phenotyping platform for positive blood culture and sterile body fluid samples
28 September 2021 - Selux next generation phenotyping now qualifies for expedited FDA review process as single-platform technology for rapid antimicrobial susceptibility testing for specified sample types.
Selux Diagnostics today announced that its next generation phenotyping platform has received breakthrough device designation from the U.S. FDA for positive blood culture and sterile body fluid samples.
